C-CCWDAmbrosia Biosciences
small molecule GPCRs, structural biology, AI molecular design
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CCWD
C-CCWDC-CCWDsmall molecule GPCRs, structural biology, AI molecular design
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Ambrosia Biosciences small molecule GPCRs, structural biology, AI molecular design
Ambrosia Biosciences is a drug discovery company developing orally delivered small-molecule therapies for obesity and other metabolic disorders. Its platform integrates cryo-EM-enabled structural biology, biophysical binding assays, AI-powered molecular design, medicinal chemistry, and high-throughput screening when needed. The company lists programs targeting GLP-1R, GIPR, and amylin, led by a team with experience across IND filings, NMEs, and FDA approvals.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Ambrosia Biosciences — Far from goals · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (4 programs at undisclosed).…
Source: Deterministic